Medicine Description glimpacare-plus 25 / 5 mg
glimpacare plus 25 / 5 mg tablets is a medication that combines two active ingredients, empagliflozin and linagliptin, to effectively manage blood glucose levels in individuals with type 2 diabetes. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion through urine. This mechanism not only aids in lowering blood sugar levels but also promotes weight loss and may have cardiovascular benefits. Linagliptin, on the other hand, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body’s own incretin hormones, which help regulate insulin secretion in response to meals. By complementing each other, these two active ingredients provide a dual approach to glycemic control, reducing both fasting and postprandial blood glucose levels.
Indications and Uses of glimpacare plus 25 / 5 mg tablets
- Management of type 2 diabetes mellitus in conjunction with diet and exercise.
- Improvement of glycemic control in adult patients.
- Possible cardiovascular risk reduction in patients with established cardiovascular disease.
Side Effects of glimpacare plus 25 / 5 mg tablets
- Hypoglycemia when used with other antidiabetic medications.
- Genital mycotic infections.
- Urinary tract infections.
- Pancreatitis.
- Gastrointestinal disturbances such as nausea or diarrhea.
Storage and Handling
Store glimpacare plus 25 / 5 mg tablets at room temperature, away from moisture and direct sunlight. Keep out of reach of children and do not use past the expiration date on the packaging.
Patient Advice and Precautions
Patients are advised to monitor their blood sugar levels regularly and adhere to dietary recommendations. It is important to discuss any existing health conditions or medications with a healthcare provider to avoid potential interactions. Stay hydrated and report any signs of infection promptly, as this medication may increase the risk of urinary tract and genital infections.